Biotech News

LifeStance Patients With Treatment-Resistant Depression See Clinically Meaningful Improvement in Symptoms After Esketamine or TMS Treatment, New Data Shows

LifeStance Health (LFST)LifeStance HealthCompany update

LifeStance Health, one of the nation's largest providers of outpatient mental healthcare, is expanding access to two specialty services for treatment-resistant depression – esketamine1 (Spravato) and transcranial magnetic stimulation2 (TMS) – as separate analyses show meaningful reductions in depression symptoms and suicidal ideation among patients receiving each treatment.

Related news

LifeStance Health

Outpatient Mental Healthcare LifeStance Health is one of the largest U.S. providers of outpatient mental-health services for children, adolescents and adults. Its clinicians treat a broad range of behavioral-health conditions through therapy and psychiatric care. Hybrid Care Network The company combines in-person practices with virtual...

Recent company news

Stock data

Close
13.34 USD
Market cap
2.96B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States